

The Columbia Lighthouse Project/Center for Suicide Risk Assessment

The Columbia Suicide Severity Rating Scale (C-SSRS)

Supporting Evidence

Last Revised
8-25-2017

Table of Contents

THE COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS): PSYCHOMETRIC EVIDENCE.....	3
TABLE 1: STUDIES SUPPORTING SPECIFIC PSYCHOMETRIC PROPERTIES	3
TABLE 2: PSYCHOMETRIC PROPERTIES OF SPECIFIC C-SSRS PREDICTORS WITH COEFFICIENTS.....	4
THE COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS): IMPACT IN PUBLIC HEALTH AND DIAGNOSTIC AND TREATMENT-MONITORING EFFECTIVENESS.....	8
TABLE 3: C-SSRS AS INTERVENTION AND MEASURE OF DIAGNOSIS AND TREATMENT.....	8
PEDIATRIC POPULATIONS BY AGE GROUP.....	11
MEDICAL SPECIALTIES	14
<i>Neurology.....</i>	<i>14</i>
<i>Oncology.....</i>	<i>14</i>
PSYCHIATRIC CONDITIONS.....	14
<i>Alzheimer’s.....</i>	<i>14</i>
<i>Autism.....</i>	<i>15</i>
<i>Bipolar Depression.....</i>	<i>15</i>
<i>Postpartum Depression.....</i>	<i>15</i>
<i>Complicated Grief.....</i>	<i>15</i>
<i>Psychosis/Schizophrenia.....</i>	<i>15</i>
<i>PTSD.....</i>	<i>16</i>
<i>Sleep.....</i>	<i>16</i>
HEALTHCARE SYSTEMS	16
OUTPATIENT SETTINGS.....	16
<i>Outpatient Psychiatry.....</i>	<i>16</i>
<i>Juvenile Justice.....</i>	<i>16</i>
<i>Integrated Primary Care.....</i>	<i>17</i>
<i>Veterans.....</i>	<i>17</i>
IN-PATIENT SETTINGS/EMERGENCY DEPARTMENTS	17
MEDICATION TREATMENT EFFICACY FOR SUICIDAL OUTCOMES	18
REVIEWS OF SUICIDE RISK ASSESSMENT TOOLS.....	18
GUIDELINES FOR TREATMENT & ASSESSMENT OF SUICIDAL OUTCOMES.....	18
LINGUISTIC AND PSYCHOMETRIC VALIDATION OF TRANSLATIONS	19
CROSS-CULTURAL SETTINGS	19

COLUMBIA SUICIDE SEVERITY RATING SCALE VERSIONS..... 22

C-SSRS CLINICAL PRACTICE SCREENER:..... 22

C-SSRS SELF-REPORT:..... 22

The Columbia Suicide Severity Rating Scale (C-SSRS): Psychometric Evidence

Table 1: Studies Supporting Specific Psychometric Properties

Psychometric Property		Studies
Clinical Utility	Predictive and/or Incremental Validity	Brent et al., 2009 [^] ; Posner et al., 2011 ^{*^} ; Mundt et al., 2013 [*] ; Arias et al. 2013 [*] ; Greist et al. 2014 [*] ; Gipson et al., 2015 [^] ; Horwitz et al., 2015 [*] ; Brown et al., 2015 [*] ; Arias et al., 2016 [*] ; Conway et al. 2016 [^] ; Madan et al. 2016 [*]
	Sensitivity to Change	Posner et al., 2011 [*] ; Ionescu et al., 2016 [*]
	Sensitivity and Specificity	Posner et al., 2011 [*] ; Mundt et al., 2013 [*] ; Viguera et al. 2015 [*] ; Madan et al. 2016 [*]
	Positive and Negative Predictive Value (PPV & NPV)	Mundt et al 2013 [*] ; Viguera et al 2015 [*]
Reliability (internal consistency)		Posner et al., 2011 ^{*^} ; Gunes et al. 2015 [^] ; Pai et al. 2015 [*] ; Madan et al. 2016 [*]
Reliability (inter-rater; multi-method agreement)		Kerr et al., 2013 ⁶ ; Brent et al., 2009 [^] ; Hesdorffer et al., 2013 [*] ; Arias et al., 2013 [*] ; Brown et al. 2015 [*] ; Gunes et al. 2015 [^]
Internal Structure (Factor Analysis)		Al-Halabi et al ., 2016b [*] ; Madan et al. 2016 [*]
Convergent Validity & Accuracy		Posner et al., 2011 [*] ; Kerr et al., 2013 [^] ; Gunes et al. 2015 [^] ; Pai et al. 2015 [*] ; Youngstrom et al. 2015 [*] ; Brown et al ., 2015 [*] ; Madan et al.2016 [*]
Divergent & Discriminant Validity		Posner et al., 2011 [*] ; Kerr et al., 2013 [^] ; Gunes et al. 2015
Cross-Cultural Validation		Danish (Conway et al. 2016 [^]); Korean (Pai et al. 2015 [*]); Turkish (Gunes et al. 2015 [*]); Spanish (Al-Halabi et al ., 2016ab [*])

* studies include adult samples; [^] studies include pediatric samples

Table 2: Psychometric Properties of Specific C-SSRS Predictors with Coefficients

Predictive Validity - Suicidal Ideation			
	Predictor	Criterion	Coefficients
Greist et al. 2014	<i>None Reported</i>	Actual, interrupted or aborted attempts	<u>All patients</u> : 0.8% incidence rate, N=4975 <u>Psychiatric patients</u> : 1.1% incidence rate, N=3184
	<i>Wish to Be Dead</i>	Actual, interrupted or aborted attempts	OR= 6.21, 95% CI = 4.18 – 9.23, p <0.001 OR= 4.99, 95% CI = 3.29 – 7.56, p <0.001
	<i>Non-Specific Active Thoughts</i>	Actual, interrupted or aborted attempts	OR= 6.69, 95% CI = 4.16 – 10.76, p <0.001 OR= 5.53, 95% CI = 3.38-9.04, p <0.001
	<i>Active with any methods (not plan) w/o intent to act</i>	Actual, interrupted or aborted attempts	OR= 11.16, 95% CI = 7.43-16.76, p <0.001 OR= 8.36, 95% CI = 5.44-12.84, p <0.001
	<i>Active with Some Intent to Act, without specific plan</i>	Actual, interrupted or aborted attempts	OR= 19.27, 95% CI = 12.97 – 28.63, p <0.001 OR= 15.24, 95% CI = 10.07-23.09, p <0.001
	<i>Active with specific plan and intent</i>	Actual, interrupted or aborted attempts	OR= 25.53, 95% CI = 16.94 – 38.47, p <0.001 OR= 18.70, 95% CI = 12.16 – 28.76, p <0.001
Posner et al. 2011	<i>Baseline worst-point</i>	Attempts	OR=1.45, 95% CI=1.07-1.98, p=0.02
		Actual, interrupted and aborted attempts	OR=1.34, 95% CI=1.05-1.70, p=0.02
	<i>Lifetime severity</i>	Attempts	OR=1.43, 95% CI=0.99-2.05, p=0.05
	<i>Severity 4-5 (any intent to act)</i>	Attempts	OR=3.26, 95% CI=1.02-10.45, p=0.047
		Actual, interrupted and aborted attempts	OR= 3.26, 95% CI=1.07-7.12, p=0.036
Horwitz et al. 2015	<i>Ideation severity 1 to 5</i>	Attempt	OR= 1.51, 95% CI= 1.24-1.84, p<0.001

Arias et al. 2016	<i>Current ideation severity 4 or 5 (with intent to die)</i>	Actual attempt or suicide 6 weeks post-ED visit	OR=1.70 95% CI 1.18-2.44, p =.004
		Actual, interrupted, aborted attempts, suicide or preparatory behavior	OR =1.52 95%CI 1.23-1.86 p <. 001
Madan et al. 2016: N=1,055 adult psych in- patients	<i>Most severe ideation within 72 hours of hospitalization</i>	Any suicide behavior within 6 months post hospitalization	r =.165, p<.01, N=275
		Psychiatric hospitalization within 6 month post initial hospitalization	r =.125, p <.05, N=275

Predictive Validity - Suicidal Behavior

	Predictor	Criterion	Coefficients
Greist et al. 2014	<i>Attempt</i>	Actual, interrupted or aborted attempts	OR=4.57, 95% CI = 3.6-5.7, p<0.001
	<i>Interrupted Attempt</i>	Actual, interrupted or aborted attempts	OR=5.55, 95% CI = 4.4-7.0, p<0.001
	<i>Aborted Attempt</i>	Actual, interrupted or aborted attempts	OR=5.09, 95% CI = 4.1-6.4, p<0.001
	<i>Preparatory behavior</i>	Actual, interrupted or aborted attempts	OR=5.69, 95% CI = 4.3-7.5, p<0.001
Horwitz et al. 2015	<i>Attempt</i>	Attempt	OR=4.80, 95% CI = 2.23-10.32, p<0.001
	<i>NSSIB item</i>	Attempt	OR=3.12, 95% CI = 1.36-7.19, p<0.01
Gipson et al. 2014	<i>NSSIB item</i>	Return ER visit	OR = 1.52; 95% CI, 1.08-2.12, p<.05
		Attempt	$\chi^2 = 4.131, df = 1, p = 0.04$

See also: Conway et al 2016.

Incremental Validity and Accuracy

Brent et al., (2009): Treatment resistant, depressed adolescent suicide attempters (N=334, ages 12-18)	<ul style="list-style-type: none"> Higher rates of suicidal (20.8% vs. 8.8%, chi squared= 9.18, df=1, p<0.002) and non-suicidal self-injury (17.6% vs. 2.2%, chi squared= 23.47, df=1, p<0.001) detected with systematic monitoring
Brown et al. (2015): psychiatric ER patients (N=250)	<ul style="list-style-type: none"> 18% (n=23) of patients with a <u>suicide attempt</u> in the past week misclassified or missed by clinical assessment. Agreement with clinical assessment for <u>suicide attempts</u> (K=0.76, p<.001) Agreement with clinical assessment of <u>non-suicidal self-injurious behavior</u> (K=0.72, p<.001)
Horwitz et al. (2014): Young adult psychiatric emergency patients (N=473)	<ul style="list-style-type: none"> Suicidal ideation added incremental validity to the prediction of future suicide attempts beyond the past suicide attempt, $X^2(1) = 7.54, p = .006$
Arias et al. (2013): 497 ER adult patients with suicidal thoughts or attempt(s)	<ul style="list-style-type: none"> 41% increase in the detection of <u>suicide attempts</u> compared to chart reviews (59% vs. 18%, difference of 41%, 95% CI= 28-55, p<0.001)

See also: Conway et al 2016.

Reliability - Suicidal Ideation (inter-rater and multi-method agreement)

Study	Ideation Type	Coefficients
Brent et al. (2009)	<i>suicidal ideation ranging from 0 to 5 (from no ideation to suicidal ideation with intent and a clear plan) monitored weekly</i>	ICC = .09, p< 0.001

Youngstrom et al. (2015)	Accuracy calibrated against “missing gold standard” latent class-derived ideation and behavior categories	$\kappa > 0.7$
Gunes et al. (2015)	Inter-rater reliability for the <u>most severe ideation scores</u> in the last month and lifetime were good	Lifetime $\kappa = 0.91$ Recent $\kappa = 0.76$
Hesdorffer et al. (2013)	Agreement between the MINI, C-SSRS and eC-SSRS for lifetime <u>suicidal ideation</u>	$\kappa = 0.80$, 95% CI = 0.72-0.89
Reliability - Suicidal Behavior		
Brown et al. (2015)	Agreement with clinical assessment for <u>attempts</u>	$\kappa = 0.76$, $P < .001$
	Agreement with clinical assessment for <u>non-suicidal self-injurious behavior</u>	$\kappa = 0.72$, $P < .001$
Youngstrom et al. (2015)	Accuracy of <u>attempt</u> : calibrated against latent class-derived categories	$\kappa > 0.8$
Brent et al. (2009)	Inter-rater reliability for a rating of <u>suicidal behavior, ranging from 0 to 5</u> (no behavior to multiple attempts during the assessment period) using the Columbia Classification Algorithm of Suicide Assessment	100% agreement
Kerr et al. (2013)	Inter-rater agreement for distinction among <u>actual, aborted, interrupted attempts, preparatory acts and any other act</u>	$\kappa = 0.88$
Hesdorffer et al. (2013)	Agreement between the MINI, C-SSRS and eC-SSRS for lifetime <u>suicidal behavior</u>	$\kappa = 0.67$, 95% CI = 0.53-0.80

The Columbia Suicide Severity Rating Scale (C-SSRS): Impact in Public Health and Diagnostic and Treatment-Monitoring Effectiveness

Table 3: C-SSRS as Intervention and Measure of Diagnosis and Treatment

Decrease in Suicide Rate: C-SSRS as Intervention	Out-Patient Mental Health Esposito, 2015	<ul style="list-style-type: none"> Centerstone - the largest provider of community-based outpatient mental health care in the U.S. The C-SSRS administered to every client at every service delivery point as part of a comprehensive Zero Suicide prevention program. In the first 20 months post-implementation, the Tennessee facilities saw a nearly 65 % reduction in the suicide rate, from 3.1 to 1.1 per 10,000 clients.
	Active Duty: US Marines Seck, 2015	<ul style="list-style-type: none"> Following training of all support staff in the C-SSRS at 16 USMC installations and implementation of mandatory C-SSRS screening by the non-healthcare personnel, including legal services, suicides in the USMC dropped by 22%, from 45 in 2013 to 34 in 2014.
	States: Utah US: UT Dept. of Human Services, 2015	<ul style="list-style-type: none"> For the first time reversed the rising suicide trend since implementing the C-SSRS as part of the comprehensive Zero Suicide program in 2015.
	Active Duty: US Army Adam Walsh, CIV DODHRA DSPO (US), (2015, personal communication)	<ul style="list-style-type: none"> At the end of 2-4 months of treatment for PTSD in active duty soldiers (N=1206), those with greater improvement in PTSD had fewer suicidal ideation symptoms on the C-SSRS.

Table 3: (Continued)

C-SSRS as an Effective Measure for Diagnosis & Treatment	Veterans Legarreta et al., 2015	<ul style="list-style-type: none"> The association of specific PTSD symptoms with suicidal ideation and behavior suggested individual PTSD symptoms as treatment target for reducing suicidal outcomes.
	Veterans Harvey et al. (2014) (suicide analyses in preparation)	<ul style="list-style-type: none"> Preliminary analyses show higher prevalence of suicidal ideation and behavior among the Vets with Bipolar Disorder than Schizophrenia. Different patterns of association with medical, psychiatric disorders and demographic characteristics between BP and SZ groups
	Medication Treatment Ionescu et al. (2016) Prakash et al. (2012)	<ul style="list-style-type: none"> Ketamine treatment effective for suicidal ideation (SI) in adults SI severity improved <u>independent</u> of acute decrease in depression and SI intensity improved <u>even if SI severity un-remitted</u> Duloxetine was effective in treating suicidal ideation among children ages 7-17 with major depression Distinguished children with improvement and deterioration

References for Psychometric Evidence and Clinical Outcomes

- Al-Halabí, S., Sáiz, P. A., Burón, P., Garrido, M., Benabarre, A., Jiménez, E., ... & Muñiz, J. (2016a). Validación de la versión en español de la Columbia-Suicide Severity Rating Scale (Escala Columbia para Evaluar el Riesgo de Suicidio). *Revista de Psiquiatría y Salud Mental*.
- Al-Halabi, S., Fernández-Peláez, AD, Burón, P., Riesco, E., Rodríguez-Revuelta, J. Posner, K. Oquendo, M., García-Portilla, MP, Saiz., P. and Bobes, J (September, 2016b). In Search of the Internal Structure of the Columbia Suicide Severity Rating Scale (C-SSRS): A Confirmatory Factor Analysis Approach. *16th European Symposium on Suicide Suicidal Behavior, Oviedo, Spain*.
- Arias, S. A., Miller, I., Camargo Jr, C. A., Sullivan, A. F., Goldstein, A. B., Allen, M. H., ... & Boudreaux, E. D. (2016). Factors Associated with Suicide Outcomes 12 Months After Screening Positive for Suicide Risk in the Emergency Department. *Psychiatric Services, 67 (2)*: 206-213.
- Arias SA, Zhang Z, Hillerns C, Sullivan AF, Boudreaux ED, Miller I, Camargo CA (2014). Using Structured Telephone Follow-up Assessments to Improve Suicide-Related Adverse Event Detection. *Suicide and Life-Threatening Behavior*44(5): 537-47.
- Brent D, Emslie G, Clarke G, Rosenbaum Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan N, Zelazny J, Onorato M, Kennard B, Mayes T, DeBar L, McCracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M (2009) Predictors of Spontaneous and Systematically Assessed Suicidal Adverse Events in the Treatment of SSRI Resistant Depression in Adolescents (TORDIA) Study. *American Journal of Psychiatry* 166(4): 418-426.
- Brown GK, Currier GW, Jager-Hyman S, et al. (2015) Detection and classification of suicidal behavior and nonsuicidal self-injury behavior in emergency departments. *J Clin Psychiatry* 76(10):1397–1403.
- Conway, P. M., Erlangsen, A., Teasdale, T. W., Jakobsen, I. S., & Larsen, K. J. (2016). Predictive Validity of the Columbia-Suicide Severity Rating Scale for Short-Term Suicidal Behavior: a Danish study of adolescents at a high risk of suicide. *Archives of suicide research, 1-15*.

8. Esposito, L. June 5, 2015. Strides in Suicide Prevention, U.S. News & World Report
9. Gipson PY, Agarwala P, Opperman KJ, Horwitz A, King CA, (2015). Columbia-Suicide Severity Rating Scale: Predictive Validity with Adolescent Psychiatric Emergency Patients. *Pediatric Emergency Care* 31(2): 88-94.
10. Greist, J. H., Mundt, J. C., Gwaltney, C. J., Jefferson, J. W., & Posner, K. (2014). Predictive Value of Baseline Electronic Columbia–Suicide Severity Rating Scale (eC–SSRS) Assessments for Identifying Risk of Prospective Reports of Suicidal Behavior During Research Participation. *Innovations in Clinical Neuroscience*, 11(9-10), 23–31.
11. Gunes A, Kilincaslan A, Eskin M (2015). Psychometric Properties of the Turkish Version of Columbia-Suicide Severity Rating Scale Among 12-18 year-old adolescents in Turkey. *AACAP 62nd Annual Meeting*, San Antonio, TX.
12. Harvey, P. D., Siever, L. J., Huang, G. D., Muralidhar, S., Zhao, H., Miller, P., ... & Brophy, M. (2014). The genetics of functional disability in schizophrenia and bipolar illness: methods and initial results for VA cooperative study# 572. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 165(4), 381-389.
13. Hesdorffer DC, French JA, Posner K, DiVentura B, Pollard J, Sperling MR, Harden CL, Krauss GL, Kanner AM (2013). Suicidal Ideation and behavior screening in intractable focal epilepsy eligible for drug trials. *Epilepsia* 54(5): 879-87.
14. Horwitz, A. G., Czyz, E. K., & King, C. A. (2015). Predicting future suicide attempts among adolescent and emerging adult psychiatric emergency patients. *Journal of Clinical Child & Adolescent Psychology*, 44(5), 751-761.
15. Ionescu, D. F., Swee, M. B., Pavone, K. J., Taylor, N., Akeju, O., Baer, L., ... & Brown, E. N. (2016). Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. *The Journal of clinical psychiatry*.
16. Kerr DCR, Gibson B, Leve LD, DeGarmo DS (2014) Young Adult Follow-up of Adolescent Girls in Juvenile Justice Using the Columbia Suicide Severity Rating Scale. *Suicide and Life Threatening Behavior* 44(2): 113-129.
17. Legarreta, M., Graham, J., North, L., Bueler, C. E., McGlade, E., & Yurgelun-Todd, D. (2015). DSM–5 posttraumatic stress disorder symptoms associated with suicide behaviors in veterans. *Psychological trauma: theory, research, practice, and policy*, 7(3), 277.
18. Madan, A., Frueh, B. C., Allen, J. G., Ellis, T. E., Rufino, K. A., Oldham, J. M., & Fowler, J. C. (2016). Psychometric reevaluation of the Columbia-Suicide Severity Rating Scale: findings from a prospective, inpatient cohort of severely mentally ill adults. *Journal of clinical psychiatry*, 77(7), e867-e873.
19. Mundt JC, Greist JH, Jefferson JW, Federica M, Mann JJ, Posner K (2013). Prediction of Suicidal Behavior in Clinical research by Lifetime Suicidal ideation and Behavior Ascertained by the Electronic Columbia-Suicide Severity Rating Scale. *Journal of Clinical Psychiatry* 74(9):887-93.
20. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ (2011). The Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings from Three Multisite Studies with Adolescents and Adults. *American Journal of Psychiatry* 168(12): 1266-77.
21. Seck, H. H. (2015, April 2). Marine suicides down 22 percent in 2014. Marine Corps Times. Retrieved from <https://www.marinecorpstimes.com/story/military/benefits/health-care/2015/04/02/marine-suicides-down-22-percent-2014/70790448/>
22. US. Utah Department of Human Services. Division of Substance Abuse and Mental Health. *State Suicide Prevention Programs FY 2015 Report*. By Thomas, D., & Meyers, K. (2015), pp. 1-11.
23. Viguera, A. C., Milano, N., Laurel, R., Thompson, N. R., Griffith, S. D., Baldessarini, R. J., & Katzan, I. L. (2015). Comparison of electronic screening for suicidal risk with the Patient Health Questionnaire Item 9 and the Columbia Suicide Severity Rating Scale in an outpatient psychiatric clinic. *Psychosomatics*, 56(5), 460-469.
24. Youngstrom, E. A., Hameed, A., Mitchell, M. A., Van Meter, A. R., Freeman, A. J., Algorta, G. P., ... & Meyer, R. E. (2015). Direct comparison of the psychometric properties of multiple interview and patient-rated assessments of suicidal ideation and behavior in an adult psychiatric inpatient sample. *The Journal of clinical psychiatry*, 76(12), 1676-1682.

REPRESENTATIVE PUBLICATIONS FOR C-SSRS USE:

DEMOGRAPHIC AND CLINICAL POPULATIONS, SETTINGS, TREATMENT EFFICACY AND

ASSESSMENT GUIDELINES

[Pediatric Populations by Age Group](#)

Ages 5-11

Glennon, J., Purper-Ouakil, D., Bakker, M., Zuddas, A., Hoekstra, P., Schulze, U., ... & Coghill, D. (2014). Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. *European child & adolescent psychiatry*, 23(12), 1149-1160. [also includes 12-17.5 age group]

Ages 6-12

Buchanan, J., Burke, T., Camacho, K., Yershova, K., Lazzaretto, D., Posner, K. (2013) Preschool Bullying and Victimization as Predictors of Suicidal Ideation in School Age: 6-year Follow-Up of the Preschool Attention Deficit/Hyperactivity Disorder Treatment Study (PATS). *1st Annual Meeting of the International Academy for Suicide Research*, Montreal, Canada.

Ages 7-13

Weinstein, S. M., Henry, D. B., Katz, A. C., Peters, A. T., & West, A. E. (2015). Treatment moderators of child-and family-focused cognitive-behavioral therapy for pediatric bipolar disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 54(2), 116-125.

Ages 6-17

Glennon, J., Purper-Ouakil, D., Bakker, M., Zuddas, A., Hoekstra, P., Schulze, U., ... & PERS Consortium. (2014). Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. *European child & adolescent psychiatry*, 23(12), 1149-1160.

Ages 7-17

Strawn, J. R., Prakash, A., Zhang, Q., Pangallo, B. A., Stroud, C. E., Cai, N., & Findling, R. L. (2015). A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 54(4), 283-293.

Emslie, G. J., Prakash, A., Zhang, Q., Pangallo, B. A., Bangs, M. E., & March, J. S. (2014). A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. *Journal of child and adolescent psychopharmacology*, 24(4), 170-179.

Ages 6-18

Wigal, S. B., Nordbrock, E., Adjei, A. L., Childress, A., Kupper, R. J., & Greenhill, L. (2015). Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study. *CNS drugs*, 29(4), 331-340.

Ages 7-17

Prakash, A., Lobo, E., Kratochvil, C. J., Tamura, R. N., Pangallo, B. A., Bullok, K. E., ... & March, J. S. (2012). An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. *Journal of child and adolescent psychopharmacology*, 22(1), 48-55.

Ages 10-18

Scott, M., Underwood, M., & Lamis, D. A. (2015). Suicide and Related-Behavior Among Youth Involved in the Juvenile Justice System. *Child and Adolescent Social Work Journal*, 32(6), 517-527.

Ages 11-17

Goodyer, I. M., Tsancheva, S., Byford, S., Dubicka, B., Hill, J., Kelvin, R., ... & Wilkinson, P. (2011). Improving mood with psychoanalytic and cognitive therapies (IMPACT): a pragmatic effectiveness superiority trial to investigate whether specialised psychological treatment reduces the risk for relapse in adolescents with moderate to severe unipolar depression: study protocol for a randomised controlled trial. *Trials*, 12(1), 175.

Ages 12-17

Findling, R. L., Cutler, A. J., Saylor, K., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Childress, A. C. (2013). A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. *Journal of child and adolescent psychopharmacology*, 23(1), 11-21.

Findling, R.L., A. Robb, and A. Bose, *Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial*. J Child Adolesc Psychopharmacol, 2013. 23(7): p. 468-80.

Ages 7-18 (for pediatric sub-sample; paper also included studies with adults)

Gibbons, R. D., Brown, C. H., Hur, K., Davis, J. M., & Mann, J. J. (2012). Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. *Archives of general psychiatry*, 69(6), 580-587.

Ages 12-17.5

Glennon, J., Purper-Ouakil, D., Bakker, M., Zuddas, A., Hoekstra, P., Schulze, U., ... & Coghill, D. (2014). Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. *European child & adolescent psychiatry*, 23(12), 1149-1160.

Ages 12-18

Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., ... & Mann, J. J. (2011). The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *American Journal of Psychiatry*, 168(12), 1266-1277.

Ages 12-18

Brent, D., Emslie, G., Clarke, G., Asarnow, J., Spirito, A., Ritz, L., ... & Keller, M. (2009). Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. *American Journal of Psychiatry*, *166*(4), 418-426.

Brent, D. A., Greenhill, L. L., Compton, S., Emslie, G., Wells, K., Walkup, J. T., ... & Turner, J. B. (2009). The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *48*(10), 987-996.

Ages 12-17

Emslie, G. J., Ventura, D., Korotzer, A., & Tourkodimitris, S. (2009). Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *48*(7), 721-729.

Ages 13-17

King, C. A., Jiang, Q., Czyz, E. K., & Kerr, D. C. (2014). Suicidal ideation of psychiatrically hospitalized adolescents has one-year predictive validity for suicide attempts in girls only. *Journal of abnormal child psychology*, *42*(3), 467-477.

Gipson, P. Y., Agarwala, P., Opperman, K. J., Horwitz, A., & King, C. A. (2014). Columbia-Suicide Severity Rating Scale: Predictive Validity with Adolescent Psychiatric Emergency Patients. *Pediatric emergency care*, *31*:2, 88-93.

Ages 14-18

Kondo, D. G., Sung, Y. H., Hellem, T. L., Fiedler, K. K., Shi, X., Jeong, E. K., & Renshaw, P. F. (2011). Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. *Journal of affective disorders*, *135*(1), 354-361.

Ages 14-19

Kaplow, J. B., Gipson, P. Y., Horwitz, A. G., Burch, B. N., & King, C. A. (2014). Emotional suppression mediates the relation between adverse life events and adolescent suicide: Implications for prevention. *Prevention Science*, *15*(2), 177-185.

King, C. A., Berona, J., Czyz, E., Horwitz, A. G., & Gipson, P. Y. (2015). Identifying Adolescents at Highly Elevated Risk for Suicidal Behavior in the Emergency Department. *Journal of child and adolescent psychopharmacology*.

Ages 15-20

Gray, K. M., Carpenter, M. J., Lewis, A. L., Klintworth, E. M., & Upadhyaya, H. P. (2012). Varenicline versus bupropion XL for smoking cessation in older adolescents: A randomized, double-blind pilot trial. *Nicotine & Tobacco Research*, *14*(2), 234-239.

Ages 15-24

Horwitz, A. G., Czyz, E. K., & King, C. A. (2015). Predicting future suicide attempts among adolescent and emerging adult psychiatric emergency patients. *Journal of Clinical Child & Adolescent Psychology*, *44*:5, 751-761.

Young Adults

Ages 15-24

Horwitz, A. G., Czyz, E. K., & King, C. A. (2015). Predicting future suicide attempts among adolescent and emerging adult psychiatric emergency patients. *Journal of Clinical Child & Adolescent Psychology*, 44:5, 751-761.

Ages 20-22

Cáceda, R., Durand, D., Cortes, E., Prendes-Alvarez, S., Moskovciak, T., Harvey, P. D., & Nemeroff, C. B. (2014). Impulsive choice and psychological pain in acutely suicidal depressed patients. *Psychosomatic medicine*, 76(6), 445-451.

Medical Specialties

Neurology

Hesdorffer, D. C., French, J. A., Posner, K., DiVentura, B., Pollard, J. R., Sperling, M. R., & Kanner, A. M. (2013). "Suicidal ideation and behavior screening in intractable focal **epilepsy** eligible for drug trials." *Epilepsia*, 1-9.

Pereira, A., Gitlin, M. J., Gross, R. A., Posner, K., & Dworkin, R. H. (2013). "Suicidality associated with antiepileptic drugs: Implications for the treatment of **neuropathic pain and fibromyalgia**." *PAIN*[®], 154(3), 345-349.

Skljarevski, V., Zhang, S., Desai, D., Alaka, K. J., Palacios, S., Miazgowski, T., & Patrick, K. (2010). Duloxetine versus placebo in patients with **chronic low back pain**: a 12-week, fixed-dose, randomized, double-blind trial. *The Journal of Pain*, 11(12), 1282-1290.

Oncology

Lucas, M. S., Brawner, B. M., Hardie, T. L., Beacham, B., Paidipati, C., Diaz, M., ... & Deatrick, J. A. (2015, September). Assessing Suicidal Ideation and Behaviors Among Survivors of Childhood Brain Tumors and Their Mothers During Sociobehavioral Research. In *Oncology nursing forum* (Vol. 42, No. 5, pp. E319-29).

Psychiatric Conditions

Alzheimer's

Nave, S., Doody, R. S., Boada, M., Grimmer, T., Savola, J. M., Delmar, P., ... & Ricci, B. (2017). Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAYfIOWer RoAD). *Journal of Alzheimer's Disease*, (Preprint), 1-12.

Delnomdedieu, M., Duvvuri, S., Li, D. J., Atassi, N., Lu, M., Brashear, H. R., ... & Kupiec, J. W. (2016). First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease. *Alzheimer's research & therapy*, 8(1), 12.

Kim, S. Y., Choi, S. H., Rollema, H., Schwam, E. M., McRae, T., Dubrava, S., & Jacobsen, J. (2013). Phase II crossover trial of varenicline in mild-to-moderate **Alzheimer's** disease. *Dementia and geriatric cognitive disorders*, 37(3-4), 232-245.

Autism

Danforth, A. L., Struble, C. M., Yazar-Klosinski, B., & Grob, C. S. (2015). MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*.

Bipolar Depression

Harvey, P. D., Siever, L. J., Huang, G. D., Muralidhar, S., Zhao, H., Miller, P., ... & Brophy, M. (2014). The genetics of functional disability in schizophrenia and bipolar illness: methods and initial results for VA cooperative study# 572. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 165(4), 381-389.

Earley, W., Durgam, S., Lu, K., DeBelle, M., Laszlovszky, I., Vieta, E., & Yatham, L. N. (2017). Tolerability of Cariprazine in the Treatment of Acute Bipolar I Mania: A Pooled Post Hoc Analysis of 3 Phase II/III Studies. *Journal of Affective Disorders*.

(*Pediatric Bipolar Disorder*) Weinstein, S. M., Henry, D. B., Katz, A. C., Peters, A. T., & West, A. E. (2015). Treatment moderators of child-and family-focused cognitive-behavioral therapy for pediatric bipolar disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 54(2), 116-125.

Postpartum Depression

Kanes, S. J., Colquhoun, H., Doherty, J., Raines, S., Hoffmann, E., Rubinow, D. R., & Meltzer-Brody, S. (2017). Open-label, proof-of-concept study of brexanolone in the treatment of **severe postpartum depression**. *Human Psychopharmacology: Clinical and Experimental*, 32(2).

Complicated Grief

Supiano, K. P., & Luptak, M. (2013). Complicated grief in older adults: A randomized controlled trial of complicated grief group therapy. *The Gerontologist*, gnt076. (6-item screener version)

GAD

Strawn, J. R., Prakash, A., Zhang, Q., Pangallo, B. A., Stroud, C. E., Cai, N., & Findling, R. L. (2015). A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 54(4), 283-293.

Psychosis/Schizophrenia

DeVylder, J. E., Jahn, D. R., Doherty, T., Wilson, C. S., Wilcox, H. C., Schiffman, J., & Hilimire, M. R. (2015). Social and psychological contributions to the co-occurrence of sub-threshold psychotic experiences and suicidal behavior. *Social psychiatry and psychiatric epidemiology*, 1-12. [young adult SELF-REPORT CSSRS]

Harvey, P. D., Siever, L. J., Huang, G. D., Muralidhar, S., Zhao, H., Miller, P., ... & Brophy, M. (2014). The genetics of functional disability in schizophrenia and bipolar illness: methods and initial results for VA cooperative study# 572. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 165(4), 381-389.

Hettige, N. C., Bani-Fatemi, A., Kennedy, J. L., & De Luca, V. (2017). Assessing the risk for suicide in schizophrenia according to migration, ethnicity and geographical ancestry. *BMC Psychiatry*, 17(1), 63.

PTSD

Legarreta, M., Graham, J., North, L., Bueler, C. E., McGlade, E., & Yurgelun-Todd, D. (2015). DSM–5 posttraumatic stress disorder symptoms associated with suicide behaviors in veterans. *Psychological trauma: theory, research, practice, and policy*, 7(3), 277.

Sleep

Ellis, T. E., Rufino, K. A., & Nadorff, M. R. (2017). Treatment of Nightmares in Psychiatric Inpatients With Imagery Rehearsal Therapy: An Open Trial and Case Series. *Behavioral Sleep Medicine*, 1-14.

Healthcare Systems

Rossom, R. C., Simon, G. E., Beck, A., Ahmedani, B. K., Steinfeld, B., Trangle, M., & Solberg, L. (2016). Facilitating Action for Suicide Prevention by Learning Health Care Systems. *Psychiatric Services*.

Outpatient Settings

Outpatient Psychiatry

Viguera, A. C., Milano, N., Laurel, R., Thompson, N. R., Griffith, S. D., Baldessarini, R. J., & Katzan, I. L. (2015). Comparison of electronic screening for suicidal risk with the Patient Health Questionnaire Item 9 and the Columbia Suicide Severity Rating Scale in an outpatient psychiatric clinic. *Psychosomatics*, 56(5), 460-469.

Juvenile Justice

Kerr, D. C., Gibson, B., Leve, L. D., & DeGarmo, D. S. (2014). Young adult follow-up of adolescent girls in juvenile justice using the Columbia Suicide Severity Rating Scale. *Suicide and life-threatening behavior*, 44(2), 113-129.

Kerr, D. C., DeGarmo, D. S., Leve, L. D., & Chamberlain, P. (2014). Juvenile justice girls' depressive symptoms and suicidal ideation 9 years after multidimensional treatment foster care. *Journal of consulting and clinical psychology*, 82(4), 684.

Rabinovitch, S. M., Kerr, D. C., Leve, L. D., & Chamberlain, P. (2014). Suicidal behavior outcomes of childhood sexual abuse: Longitudinal study of adjudicated girls. *Suicide and life-threatening behavior*.

Scott, M., Underwood, M., & Lamis, D. A. (2015). Suicide and Related-Behavior Among Youth Involved in the Juvenile Justice System. *Child and Adolescent Social Work Journal*, 32(6), 517-527.

Integrated Primary Care

Kearney, L. K., Wray, L. O., Dollar, K. M., & King, P. R. (2015). Establishing Measurement-based Care in Integrated Primary Care: Monitoring Clinical Outcomes Over Time. *Journal of clinical psychology in medical settings*, 22(4), 213-227.

Veterans

Zisook, S., Tal, I., Weingart, K., Hicks, P., Davis, L. L., Chen, P., ... & Pilkinton, P. D. (2016). Characteristics of US Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report. *Journal of Affective Disorders*, 206, 232-240.

Legarreta, M., Graham, J., North, L., Bueller, C. E., McGlade, E., & Yurgelun-Todd, D. (2015). DSM–5 posttraumatic stress disorder symptoms associated with suicide behaviors in veterans. *Psychological trauma: theory, research, practice, and policy*, 7(3), 277.

Harvey, P. D., Siever, L. J., Huang, G. D., Muralidhar, S., Zhao, H., Miller, P., ... & Brophy, M. (2014). The genetics of functional disability in schizophrenia and bipolar illness: methods and initial results for VA cooperative study# 572. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 165(4), 381-389.

In-Patient Settings/Emergency Departments

Allen, J. G., Fowler, J. C., Madan, A., Ellis, T. E., Oldham, J. M., & Frueh, B. C. (2017). Discovering the impact of psychotherapeutic hospital treatment for adults with serious mental illness. *Bulletin of the Menninger Clinic*, 81(1), 1-38.

Madan, A., Frueh, B. C., Allen, J. G., Ellis, T. E., Rufino, K. A., Oldham, J. M., & Fowler, J. C. (2016). Psychometric reevaluation of the Columbia-Suicide Severity Rating Scale: findings from a prospective, inpatient cohort of severely mentally ill adults. *Journal of clinical psychiatry*, 77(7), e867-e873.

Arias, S. A., Miller, I., Camargo Jr, C. A., Sullivan, A. F., Goldstein, A. B., Allen, M. H., ... & Boudreaux, E. D. (2015). Factors Associated with Suicide Outcomes 12 Months After Screening Positive for Suicide Risk in the Emergency Department. *Psychiatric Services*.

Brown, G. K., Currier, G. W., Jager-Hyman, S., & Stanley, B. (2015). Detection and classification of suicidal behavior and nonsuicidal self-injury behavior in emergency departments. *The Journal of clinical psychiatry*, 76(10), 1-478.

Horwitz, A. G., Czyz, E. K., & King, C. A. (2015). Predicting future suicide attempts among adolescent and emerging adult psychiatric emergency patients. *Journal of Clinical Child & Adolescent Psychology*, 44(5), 751-761.

King, C. A., Berona, J., Czyz, E., Horwitz, A. G., & Gipson, P. Y. (2015). Identifying adolescents at highly elevated risk for suicidal behavior in the emergency department. *Journal of child and adolescent psychopharmacology*, 25(2), 100-108.

Gipson, P. Y., Agarwala, P., Opperman, K. J., Horwitz, A., & King, C. A. (2015). Columbia-suicide severity rating scale: predictive validity with adolescent psychiatric emergency patients. *Pediatric emergency care*, 31(2), 88-94.

Teti, G. L., Rebok, F., Grndas, L. N., Rodante, D., Fogola, A., & Daray, F. M. (2014). Patients hospitalized for suicidal ideation and suicide attempt in a Mental Health Hospital: Clinico-demographical features and 6-month follow-up. *Vertex*, 25(115), 203-212.

Arias, S. A., Zhang, Z., Hillerns, C., Sullivan, A. F., Boudreaux, E. D., Miller, I., & Camargo, C. A. (2014). Using structured telephone follow-up assessments to improve suicide-related adverse event detection. *Suicide and life-threatening behavior*, 44(5), 537-547.

King, C. A., Jiang, Q., Czyz, E. K., & Kerr, D. C. (2014). Suicidal ideation of psychiatrically hospitalized adolescents has one-year predictive validity for suicide attempts in girls only. *Journal of abnormal child psychology*, 42(3), 467-477.

Kaplow, J. B., Gipson, P. Y., Horwitz, A. G., Burch, B. N., & King, C. A. (2014). Emotional suppression mediates the relation between adverse life events and adolescent suicide: Implications for prevention. *Prevention Science*, 15(2), 177-185.

Cáceda, R., Durand, D., Cortes, E., Prendes-Alvarez, S., Moskovciak, T., Harvey, P. D., & Nemeroff, C. B. (2014). Impulsive choice and psychological pain in acutely suicidal depressed patients. *Psychosomatic medicine*, 76(6), 445-451.

Boudreaux, E. D., Miller, I., Goldstein, A. B., Sullivan, A. F., Allen, M. H., Manton, A. P., ... & Camargo, C. A. (2013). The emergency department safety assessment and follow-up evaluation (ED-SAFE): method and design considerations. *Contemporary clinical trials*, 36(1), 14-24.

Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., ... & Mann, J. J. (2011). The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *American Journal of Psychiatry*, 168(12), 1266-1277.

Medication Treatment Efficacy for Suicidal Outcomes

Ionescu, D. F., Swee, M. B., Pavone, K. J., Taylor, N., Akeju, O., Baer, L., ... & Brown, E. N. (2016). Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. *The Journal of clinical psychiatry*.

Prakash, A., Lobo, E., Kratochvil, C. J., Tamura, R. N., Pangallo, B. A., Bullok, K. E., Quinlan, T., Emslie, G.J. & March, J. S. (2012). An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. *Journal of Child and Adolescent Psychopharmacology*, 22(1), 48-55.

Reviews of Suicide Risk Assessment Tools

Bolton, J. M., Gunnell, D., & Turecki, G. (2015). Suicide risk assessment and intervention in people with mental illness. *British Medical Journal*, 351(8034).

Posner, K., Buchanan, J., Amira, L., Yershova, K., Lesser, A., Goldstein, E. (2014). Identification and screening of suicide risk. In S. Koslow, C., Nemeroff, P. Ruiz, (eds.), *A Concise Guide to Understanding Suicide: Epidemiology, Pathophysiology and Prevention*. Cambridge University Press.

Guidelines for Treatment & Assessment of Suicidal Outcomes

Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., ... & Carli, V. (2012). The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. *European Psychiatry*, 27(2), 129-141.

US Food and Drug Administration. *Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials*.

<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm315156.htm>. Rockville, MD: US Department of Health and Human Services; 2012.

Linguistic and Psychometric Validation of Translations

Gratalup, G., Fernander, N., Fuller, D.S. and Posner, K (2013). Translation of the Columbia Suicide Severity Rating Scale for Use in 33 Countries. ISCTM 9th Annual Scientific Meeting, Washington D.C.

Al-Halabí, S., Sáiz, P. A., Burón, P., Garrido, M., Benabarre, A., Jiménez, E., ... & Muñoz, J. (2016). Validación de la versión en **español** de la Columbia-Suicide Severity Rating Scale (Escala Columbia para Evaluar el Riesgo de Suicidio). *Revista de Psiquiatría y Salud Mental*.

Al-Halabi, S., Fernández-Peláez, AD, Burón, P., Riesco, E., Rodríguez-Revuelta, J. Posner, K. Oquendo, M., García-Portilla, MP, Saiz, P. and Bobes, J (September, 2016). In Search of the Internal Structure of the Columbia Suicide Severity Rating Scale (C-SSRS): A Confirmatory Factor Analysis Approach. *16th European Symposium on Suicide Suicidal Behavior*, Oviedo, Spain. [**Spanish**]

Conway, P. M., Erlangsen, A., Teasdale, T. W., Jakobsen, I. S., & Larsen, K. J. (2016). Predictive Validity of the Columbia-Suicide Severity Rating Scale for Short-Term Suicidal Behavior: a **Danish** study of adolescents at a high risk of suicide. *Archives of suicide research*, 1-15.

Gunes A, Kilincaslan A, Eskin M (2015). Psychometric Properties of the **Turkish** Version of Columbia-Suicide Severity Rating Scale Among 12-18 year-old adolescents in Turkey. AACAP 62nd Annual Meeting, San Antonio, TX.

Pai, D., Woo, J. M., Son, M. H., & Lee, C. (2015). The Reliability and Validity of the Korean Version of Columbia-Suicide Severity Rating Scale in Alcohol Dependent Patients. *Journal of Korean Neuropsychiatric Association*, 54(2), 222-227.

Cross-Cultural Settings

Latin America (Spanish)

Teti, G. L., Rebok, F., Grndas, L. N., Rodante, D., Fogola, A., & Daray, F. M. (2014). Patients hospitalized for suicidal ideation and suicide attempt in a Mental Health Hospital: Clinico-demographical features and 6-month follow-up. *Vertex*, 25(115), 203-212.

Argentina

Frye, M.A., Amchin, J., Bauer, M., Adler, C., Yang, R., & Ketter, T.A. (2015). Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments. *International journal of bipolar disorders*, 3(1), 1-9.

Australia

van Spijker, B. A., Caelear, A. L., Batterham, P. J., Mackinnon, A. J., Gosling, J. A., Kerkhof, A. J., ... & Christensen, H. (2015). Reducing suicidal thoughts in the Australian general population through web-based self-help: study protocol for a randomized controlled trial. *Trials*, 16(1), 589-589.

China

Wang, H., Xue, Y., Chen, Y., Zhang, R., Wang, H., Zhang, Y., ... & Tan, Q. (2013). Efficacy of repetitive transcranial magnetic stimulation in the prevention of relapse of depression: study protocol for a randomized controlled trial. *Trials*, 14(1), 338.

Croatia

Sisek-Šprem, M. (2012). Demographic characteristics of aggressive patients with schizophrenia. *Socijalna psihijatrija*, 40(3), 213-220.

Ethiopia

Borba, C. P., Fekadu, A., Teferra, S., Bekele, D., Shibre, T., Oppenheim, C. E., ... & Henderson, D. C. (2014). A placebo-controlled trial of folate with B12 in patients with schizophrenia with residual symptoms in Ethiopia using a sequential parallel comparison design. *British Journal of Medicine and Medical Research*, 4(23), 4090.

France

Welniarz, B., & Saintoyan, F. (2015). Dépression de l'enfant et de l'adolescent: place du traitement médicamenteux et de l'hospitalisation. *Neuropsychiatrie de l'Enfance et de l'Adolescence*.

Germany

von Klitzing, K. (2008). Depressionen im Kindes und Jugendalter. *Kinder-und Jugendmedizin*, 8(1), 18-23.

Hungary

Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, D.T., Zalsman, G., ... & Carli, V. (2012). Az Európai Pszichiátriai Szövetség (European Psychiatric Association, EPA) útmutatója az öngyilkosság kezelésére és megelőzésére. *Neuropsychopharmacol Hung*, 14(2), 113-136.

Indonesia

Pratiwi, J., & Undarwati, A. (2014). SUICIDE IDEATION PADA REMAJA DI KOTA SEMARANG. *Developmental and Clinical Psychology*, 3(1).

India

Pasi, S., Singh, P. K., Pandey, R. K., Dikshit, P. C., Jiloha, R. C., & Rao, V. R. (2015). Evaluation of psychiatric and genetic risk factors among primary relatives of suicide completers in Delhi NCR region, India. *Psychiatry research*, 229(3), 933-939.

Bansal, K. (2013). Pre and Post-Psychosocial Factors of Subjects enrolled in Phase-III Oncology Clinical Trials. *Journal of Academia and Industrial Research (JAIR)*, 2(5), 312.

Korea

Lim, M., Lee, S., & Park, J. I. (2015). Characteristics of Korean Suicide Attempters. *Journal of Korean Neuropsychiatric Association*, 54(2), 209-215.

Spain

Teti, G. L., Rebok, F., Grndas, L. N., Rodante, D., Fogola, A., & Daray, F. M. (2014). Patients hospitalized for suicidal ideation and suicide attempt in a Mental Health Hospital: Clinico-demographical features and 6-month follow-up. *Vertex*, 25(115), 203-212.

Sri Lanka

Suraweera, C., Hanwella, R., Sivayokan, S., & de Silva, V. (2013). Rating Scales validated for Sri Lankan populations. *Sri Lanka J of Psychiatry*, 4(2), 16-24.

Columbia Suicide Severity Rating Scale Versions

C-SSRS clinical practice screener:

Henderson, J. L., Cheung, A., Cleverley, K., Chaim, G., Moretti, M. E., de Oliveira, C., ... & Herzog, T. (2017). Integrated collaborative care teams to enhance service delivery to youth with mental health and substance use challenges: protocol for a pragmatic randomised controlled trial. *BMJ open*, 7(2).

C-SSRS self-report:

Viguera, A. C., Milano, N., Laurel, R., Thompson, N. R., Griffith, S. D., Baldessarini, R. J., & Katzan, I. L. (2015). Comparison of electronic screening for suicidal risk with the Patient Health Questionnaire Item 9 and the Columbia Suicide Severity Rating Scale in an outpatient psychiatric clinic. *Psychosomatics*, 56(5), 460-469.